Best AI Therapy
Menu
For Consumers
Best AI Therapy Apps Best CBT Apps Is AI Therapy Effective?
For Therapists
Best AI Tools for Therapists Best AI Clinical Notes How AI Helps Therapists
Compare
Wysa vs Youper Upheal vs Mentalyc
Guides
Clinical Evidence For Employers: AI Benefits Compare Employer Platforms
Pricing Comparison Methodology About

Mental Health Information

This content is for informational purposes only. AI therapy tools are not substitutes for professional mental health treatment. Always consult a licensed mental health professional.

In crisis?

  • Call 988 (Suicide & Crisis Lifeline)
  • Text HOME to 741741 — free, confidential, 24/7.
Service status: Woebot Health discontinued its consumer-facing app in June 2025. New consumer signups are no longer available.

Woebot Shutdown Explained: What Happened and What to Use Instead

In June 2025, Woebot Health shut down the consumer-facing version of the most clinically researched AI therapy chatbot ever built. With multiple peer-reviewed randomized controlled trials behind it, Woebot was the gold standard of evidence-based AI mental health products. Its consumer shutdown was a meaningful moment for the field — and a useful case study in why clinical evidence is necessary but not sufficient for a sustainable consumer business.

On this page
  1. What Happened
  2. Why It Matters
  3. Why the Shutdown Likely Happened
  4. What This Means for the Industry
  5. What to Use Instead
  6. Bottom Line

What Happened

Woebot Health, founded by clinical psychologist Dr. Alison Darcy and a Stanford-affiliated team in 2017, announced in 2025 that it would discontinue its consumer mobile app effective June of that year. Existing users were notified, and the app was removed from new signups. Woebot Health publicly framed the move as a strategic refocus toward enterprise, payer, and health-system licensing — selling its underlying technology to organizations rather than selling subscriptions to individuals.

Why It Matters

Woebot was not a fringe product. It had:

  • Multiple peer-reviewed RCTs published in venues including JMIR Mental Health
  • FDA Breakthrough Device designation for postpartum depression
  • Years of public visibility, academic citations, and clinical respect
  • A clinically authored, rule-based design that delivered consistent CBT interventions

If a product with this much clinical and reputational capital cannot sustain a consumer subscription business, the industry should pay attention.

Why the Shutdown Likely Happened

Woebot Health did not publish a detailed financial post-mortem. From the outside, several plausible factors converged:

1. LLM-Based Competition Changed the Category

Between 2022 and 2025, large language model chatbots transformed user expectations for AI conversation. Woebot's rule-based, clinically authored conversation flows — once an asset for safety and consistency — began to feel rigid compared to LLM-powered competitors and to general products like ChatGPT. Users now expected naturalistic, free-form interaction.

2. Consumer Mental Health Subscription Economics Are Harsh

Subscription mental health apps face high churn, rising customer acquisition costs, and meaningful refund and chargeback rates. The category as a whole has consolidated. Standalone consumer products with limited monetization options have struggled even when their clinical performance is excellent.

3. Regulatory Pathways Are Slow

FDA Breakthrough Device designation is not the same as a marketed prescription digital therapeutic. Pursuing a regulated pathway is expensive, slow, and uncertain. The promise of insurance reimbursement for prescription digital mental health products has not materialized at the scale once anticipated.

4. Enterprise B2B Has Better Unit Economics

Selling licensed deployments to large health systems, payers, and employers offers higher contract values, lower churn, and more predictable revenue than consumer subscriptions. Refocusing on B2B is a rational strategic choice for a company with valuable IP and a strong research portfolio.

What This Means for the Industry

  • Clinical evidence is necessary but not sufficient. Strong RCTs do not guarantee a sustainable consumer business. Distribution, monetization, and market timing matter as much as efficacy.
  • The most clinically validated app available today is Wysa. With 30+ peer-reviewed publications, Wysa now holds the position Woebot held — and remains operational with a consumer subscription business.
  • Consumer mental health has consolidated. Multiple products were discontinued in 2024-2025 (Bloom by Spring Health, Woebot consumer), and the sector has seen major acquisitions — see our explainer on the Talkspace–UHS acquisition. Surviving players need both evidence and economics.
  • Enterprise B2B is the durable model for AI mental health. Tools that sell to therapists, practices, payers, and health systems have stronger paths to sustainability than direct-to-consumer subscriptions.

What Former Woebot Users Should Use Instead

  • Wysa — the strongest direct replacement. Most clinically validated consumer AI therapy app available today.
  • MindDoc — for users who valued Woebot's structured check-ins; offers validated mood and symptom tracking.
  • Elomia — for users who want a more conversational chatbot experience.
  • Talkiatry — for US adults whose symptoms warrant professional care and who have insurance.
  • Local licensed therapy — for anyone whose mental health needs exceed what an app can provide.

Bottom Line

Woebot's consumer shutdown was not a verdict on AI therapy chatbots. It was a verdict on a particular business model in a particular moment. The clinical research Woebot produced will outlast its consumer product, and its design principles continue to inform every serious AI mental health app that came after it. For users in 2026 looking for a clinically validated AI therapy chatbot they can actually use, Wysa is the answer.

In crisis? Call 988 or text HOME to 741741 — free, confidential, 24/7